• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肠道微生物群可预防 MCD 饮食诱导的脂肪性肝炎。

Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.

机构信息

Department of Internal Medicine III, University Hospital RWTH Aachen, 52074 Aachen, Germany.

Department of Pathology, Klinikum Braunschweig, 38118 Braunschweig, Germany.

出版信息

Int J Mol Sci. 2019 Jan 14;20(2):308. doi: 10.3390/ijms20020308.

DOI:10.3390/ijms20020308
PMID:30646522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6358781/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in western countries, with a continuously rising incidence. Gut-liver communication and microbiota composition have been identified as critical drivers of the NAFLD progression. Hence, it has been shown that microbiota depletion can ameliorate high-fat diet or western-diet induced experimental Non-alcoholic steatohepatitis (NASH). However, its functional implications in the methionine-choline dietary model, remain incompletely understood. Here, we investigated the physiological relevance of gut microbiota in methionine-choline deficient (MCD) diet induced NASH. Experimental liver disease was induced by 8 weeks of MCD feeding in wild-type (WT) mice, either with or without commensal microbiota depletion, by continuous broad-spectrum antibiotic (AB) treatment. MCD diet induced steatohepatitis was accompanied by a reduced gut microbiota diversity, indicating intestinal dysbiosis. MCD treatment prompted macroscopic shortening of the intestine, as well as intestinal villi in histology. However, gut microbiota composition of MCD-treated mice, neither resembled human NASH, nor did it augment the intestinal barrier integrity or intestinal inflammation. In the MCD model, AB treatment resulted in increased steatohepatitis activity, compared to microbiota proficient control mice. This phenotype was driven by pronounced neutrophil infiltration, while AB treatment only slightly increased monocyte-derived macrophages (MoMF) abundance. Our data demonstrated the differential role of gut microbiota, during steatohepatitis development. In the context of MCD induced steatohepatitis, commensal microbiota was found to be hepatoprotective.

摘要

非酒精性脂肪性肝病(NAFLD)是西方国家最常见的肝脏疾病,其发病率持续上升。肠道-肝脏通讯和微生物群落组成已被确定为 NAFLD 进展的关键驱动因素。因此,已经表明微生物群落耗竭可以改善高脂肪饮食或西方饮食诱导的实验性非酒精性脂肪性肝炎(NASH)。然而,其在蛋氨酸-胆碱饮食模型中的功能意义仍不完全清楚。在这里,我们研究了肠道微生物群在蛋氨酸-胆碱缺乏(MCD)饮食诱导的 NASH 中的生理相关性。通过连续广谱抗生素(AB)处理,在野生型(WT)小鼠中用 8 周的 MCD 喂养诱导实验性肝病,要么存在共生微生物群落耗竭,要么不存在。MCD 饮食诱导的肝炎伴随着肠道微生物多样性的降低,表明肠道菌群失调。MCD 处理促使肠道宏观缩短,组织学上的肠绒毛也变短。然而,MCD 处理小鼠的肠道微生物群落组成既不像人类 NASH,也不会增加肠道屏障完整性或肠道炎症。在 MCD 模型中,与具有共生微生物群落的对照小鼠相比,AB 处理导致肝脂肪变性活性增加。这种表型是由明显的中性粒细胞浸润驱动的,而 AB 处理仅略微增加单核细胞衍生的巨噬细胞(MoMF)的丰度。我们的数据表明,肠道微生物群在肝脂肪变性发展过程中发挥了不同的作用。在 MCD 诱导的肝脂肪变性中,共生微生物群被发现具有肝脏保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07cf/6358781/77e7a89e722d/ijms-20-00308-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07cf/6358781/77e7a89e722d/ijms-20-00308-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07cf/6358781/77e7a89e722d/ijms-20-00308-g002.jpg

相似文献

1
Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.肠道微生物群可预防 MCD 饮食诱导的脂肪性肝炎。
Int J Mol Sci. 2019 Jan 14;20(2):308. doi: 10.3390/ijms20020308.
2
Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.蛋氨酸-胆碱缺乏饮食诱导的非酒精性脂肪性肝炎发生过程中肠道微生物组和代谢组的动态变化。
World J Gastroenterol. 2018 Jun 21;24(23):2468-2481. doi: 10.3748/wjg.v24.i23.2468.
3
Rifaximin alleviates MCD diet-induced NASH in mice by restoring the gut microbiota and intestinal barrier.利福昔明通过恢复肠道微生物群和肠道屏障缓解 MCD 饮食诱导的 NASH 小鼠模型的非酒精性脂肪性肝炎。
Life Sci. 2024 Nov 15;357:123095. doi: 10.1016/j.lfs.2024.123095. Epub 2024 Oct 3.
4
Impact of global PTP1B deficiency on the gut barrier permeability during NASH in mice.全球 PTP1B 缺乏对 NASH 小鼠肠道屏障通透性的影响。
Mol Metab. 2020 May;35:100954. doi: 10.1016/j.molmet.2020.01.018. Epub 2020 Feb 6.
5
A methionine-choline-deficient diet induces nonalcoholic steatohepatitis and alters the lipidome, metabolome, and gut microbiome profile in the C57BL/6J mouse.蛋氨酸-胆碱缺乏饮食诱导 C57BL/6J 小鼠非酒精性脂肪性肝炎,并改变其脂质组、代谢组和肠道微生物组谱。
Biochim Biophys Acta Mol Cell Biol Lipids. 2024 Dec;1869(8):159545. doi: 10.1016/j.bbalip.2024.159545. Epub 2024 Jul 31.
6
Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model.枸橼酸莫沙必利可改善肠道乳酸杆菌丰度和血浆胰高血糖素样肽-1水平,从而改善非酒精性脂肪性肝炎。
Am J Physiol Gastrointest Liver Physiol. 2015 Jan 15;308(2):G151-8. doi: 10.1152/ajpgi.00198.2014. Epub 2014 Nov 26.
7
Soyasaponin A Alleviates Steatohepatitis Possibly through Regulating Bile Acids and Gut Microbiota in the Methionine and Choline-Deficient (MCD) Diet-induced Nonalcoholic Steatohepatitis (NASH) Mice.大豆皂苷 A 可能通过调节蛋氨酸和胆碱缺乏(MCD)饮食诱导的非酒精性脂肪性肝炎(NASH)小鼠的胆汁酸和肠道微生物群来缓解肝脂肪变性。
Mol Nutr Food Res. 2021 Jul;65(14):e2100067. doi: 10.1002/mnfr.202100067. Epub 2021 Jun 10.
8
Altered Gut Microbiota Composition and Immune Response in Experimental Steatohepatitis Mouse Models.实验性脂肪性肝炎小鼠模型中肠道微生物群组成及免疫反应的改变
Dig Dis Sci. 2017 Feb;62(2):396-406. doi: 10.1007/s10620-016-4393-x. Epub 2016 Dec 2.
9
Indole supplementation ameliorates MCD-induced NASH in mice.吲哚补充剂可改善 MCD 诱导的小鼠 NASH。
J Nutr Biochem. 2022 Sep;107:109041. doi: 10.1016/j.jnutbio.2022.109041. Epub 2022 May 11.
10
A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet.高脂肪饮食和蛋氨酸-胆碱缺乏饮食动物模型中非酒精性脂肪性肝病基因表达谱的比较。
Molecules. 2022 Jan 27;27(3):858. doi: 10.3390/molecules27030858.

引用本文的文献

1
Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota.肝脏组织病理学益处与微生物代价:口服万古霉素可减轻非酒精性脂肪性肝病,但会破坏盲肠微生物群。
Int J Mol Sci. 2025 Sep 4;26(17):8616. doi: 10.3390/ijms26178616.
2
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics.非酒精性脂肪性肝病中的肠道微生物群:病理生理学、诊断与治疗
World J Hepatol. 2025 Jun 27;17(6):106849. doi: 10.4254/wjh.v17.i6.106849.
3
The gut microbiome and metabolomic alterations underlying colitis-induced encephalopathy in mice: mechanistic insight.

本文引用的文献

1
Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism.抗生素诱导的微生物组耗竭通过影响肠道信号和结肠代谢来改变代谢稳态。
Nat Commun. 2018 Jul 20;9(1):2872. doi: 10.1038/s41467-018-05336-9.
2
Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis.中性粒细胞与肝星状细胞的相互作用促进实验性脂肪性肝炎中的纤维化
Cell Mol Gastroenterol Hepatol. 2018 Jan 8;5(3):399-413. doi: 10.1016/j.jcmgh.2018.01.003. eCollection 2018 Mar.
3
Role of bile acids in the gut-liver axis.
小鼠结肠炎诱导性脑病背后的肠道微生物群和代谢组学改变:机制洞察
Behav Brain Funct. 2025 Jun 12;21(1):17. doi: 10.1186/s12993-025-00283-0.
4
Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病中肠道微生物群的作用机制及治疗进展
Gut Microbes. 2025 Dec;17(1):2500099. doi: 10.1080/19490976.2025.2500099. Epub 2025 May 20.
5
Differences in Fatty Acid Metabolism between MCDD and HFD Induced Metabolic Dysfunction-associated Fatty Liver Disease Model Mice.MCDD和高脂饮食诱导的代谢功能障碍相关脂肪性肝病模型小鼠脂肪酸代谢的差异
Biol Proced Online. 2025 Apr 14;27(1):14. doi: 10.1186/s12575-025-00276-3.
6
Dietary index for gut microbiota and its protective role against kidney stones: evidence of diabetes as a mediator from NHANES cross-sectional data.肠道微生物群的饮食指数及其对肾结石的保护作用:来自美国国家健康和营养检查调查横断面数据的糖尿病作为中介因素的证据
Front Nutr. 2025 Feb 11;12:1532313. doi: 10.3389/fnut.2025.1532313. eCollection 2025.
7
The Importance of Gut Microbiota on Choline Metabolism in Neurodegenerative Diseases.肠道微生物群对神经退行性疾病中胆碱代谢的重要性。
Biomolecules. 2024 Oct 23;14(11):1345. doi: 10.3390/biom14111345.
8
Development of non-alcoholic steatohepatitis is associated with gut microbiota but not with oxysterol enzymes CH25H, EBI2, or CYP7B1 in mice.非酒精性脂肪性肝炎的发生与肠道微生物群有关,但与小鼠中的胆甾醇 25-羟化酶、EBI2 或 CYP7B1 等氧化固醇酶无关。
BMC Microbiol. 2024 Feb 28;24(1):69. doi: 10.1186/s12866-024-03195-7.
9
Recent evaluation about inflammatory mechanisms in nonalcoholic fatty liver disease.非酒精性脂肪性肝病炎症机制的最新评估
Front Pharmacol. 2023 Mar 16;14:1081334. doi: 10.3389/fphar.2023.1081334. eCollection 2023.
10
Myeloid TLR4 signaling promotes post-injury withdrawal resolution of murine liver fibrosis.髓样Toll样受体4信号通路促进小鼠肝纤维化损伤后消退。
iScience. 2023 Feb 16;26(3):106220. doi: 10.1016/j.isci.2023.106220. eCollection 2023 Mar 17.
胆汁酸在肠-肝轴中的作用。
J Hepatol. 2018 May;68(5):1083-1085. doi: 10.1016/j.jhep.2017.11.025. Epub 2018 Mar 5.
4
Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.炎症性单核细胞募集的治疗性抑制可减少脂肪性肝炎和肝纤维化。
Hepatology. 2018 Apr;67(4):1270-1283. doi: 10.1002/hep.29544. Epub 2018 Feb 19.
5
Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications.瘦人非酒精性脂肪性肝病:特征与影响
J Clin Transl Hepatol. 2017 Sep 28;5(3):216-223. doi: 10.14218/JCTH.2016.00068. Epub 2017 Jul 5.
6
Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment.短期摄入富含果糖、脂肪和胆固醇的饮食会导致小鼠肝脂肪变性:抗生素治疗的影响。
Nutrients. 2017 Sep 14;9(9):1013. doi: 10.3390/nu9091013.
7
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.一项关于西尼利尤单抗治疗伴有纤维化的非酒精性脂肪性肝炎的随机、安慰剂对照试验。
Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.
8
MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data.微生物组分析工具:一个基于网络的工具,用于对微生物组数据进行全面的统计、可视化和荟萃分析。
Nucleic Acids Res. 2017 Jul 3;45(W1):W180-W188. doi: 10.1093/nar/gkx295.
9
Liver macrophages in tissue homeostasis and disease.组织稳态和疾病中的肝巨噬细胞。
Nat Rev Immunol. 2017 May;17(5):306-321. doi: 10.1038/nri.2017.11. Epub 2017 Mar 20.
10
Targeting hepatic macrophages to treat liver diseases.针对肝巨噬细胞治疗肝脏疾病。
J Hepatol. 2017 Jun;66(6):1300-1312. doi: 10.1016/j.jhep.2017.02.026. Epub 2017 Mar 4.